EULAV Asset Management’s Thermo Fisher Scientific TMO Stock Holding History

EULAV Asset Management’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2,400	Closed	-$1.18M	–	162
2026 Q1	$1.18M	Sell	2,400 -27,000	-92%	-$14.7M	0.04%	133
2025 Q4	$17M	Hold	29,400	–	–	0.45%	70
2025 Q3	$14.3M	Hold	29,400	–	–	0.33%	83
2025 Q2	$11.9M	Hold	29,400	–	–	0.28%	89
2025 Q1	$14.6M	Hold	29,400	–	–	0.36%	72
2024 Q4	$15.3M	Sell	29,400 -2	-0%	-$1.1K	0.37%	77
2024 Q3	$18.2M	Buy	29,402 +2	+0%	+$1.18K	0.44%	64
2024 Q2	$16.3M	Hold	29,400	–	–	0.44%	64
2024 Q1	$17.1M	Sell	29,400 -3	-0%	-$1.68K	0.47%	58
2023 Q4	$15.6M	Sell	29,403 -38,923	-57%	-$18.8M	0.48%	60
2023 Q3	$34.6M	Hold	68,326	–	–	1.26%	26
2023 Q2	$35.6M	Hold	68,326	–	–	1.33%	20
2023 Q1	$39.4M	Sell	68,326 -30,674	-31%	-$17.3M	1.55%	15
2022 Q4	$54.5M	Sell	99,000 -4,000	-4%	-$2.12M	2.34%	4
2022 Q3	$52.2M	Hold	103,000	–	–	2.31%	4
2022 Q2	$56M	Sell	103,000 -29,000	-22%	-$16M	2.31%	4
2022 Q1	$78M	Hold	132,000	–	–	2.32%	5
2021 Q4	$88.1M	Sell	132,000 -220	-0.2%	-$137K	2.22%	3
2021 Q3	$75.5M	Sell	132,220 -6	-0%	-$3.29K	1.99%	4
2021 Q2	$66.7M	Sell	132,226 -2	-0%	-$944	1.76%	5
2021 Q1	$60.3M	Sell	132,228 -5,000	-4%	-$2.39M	1.62%	7
2020 Q4	$63.9M	Buy	137,228 +28	+0%	+$13.1K	1.67%	5
2020 Q3	$60.6M	Sell	137,200 -36	-0%	-$14.9K	1.79%	6
2020 Q2	$49.7M	Buy	137,236 +36	+0%	+$12.1K	1.63%	10
2020 Q1	$38.9M	Buy	137,200 +17,000	+14%	+$5.36M	1.56%	10
2019 Q4	$39M	Buy	120,200 +9,600	+9%	+$2.91M	1.35%	16
2019 Q3	$32.2M	Buy	110,600 +39,500	+56%	+$11.3M	1.19%	21
2019 Q2	$20.9M	Buy	71,100 +22,500	+46%	+$6.2M	0.78%	39
2019 Q1	$13.4M	Buy	48,600 +9,300	+24%	+$2.31M	0.55%	58
2018 Q4	$8.79M	Hold	39,300	–	–	0.44%	77
2018 Q3	$9.59M	Hold	39,300	–	–	0.41%	77
2018 Q2	$8.14M	Hold	39,300	–	–	0.37%	88
2018 Q1	$8.11M	Hold	39,300	–	–	0.39%	84
2017 Q4	$7.46M	Hold	39,300	–	–	0.35%	98
2017 Q3	$7.44M	Hold	39,300	–	–	0.35%	95
2017 Q2	$6.86M	Hold	39,300	–	–	0.34%	105
2017 Q1	$6.04M	Buy	39,300 +1,000	+3%	+$153K	0.31%	112
2016 Q4	$5.4M	Sell	38,300 -314	-0.8%	-$46.3K	0.29%	121
2016 Q3	$6.14M	Buy	38,614 +314	+0.8%	+$48.4K	0.33%	114
2016 Q2	$5.66M	Hold	38,300	–	–	0.31%	116
2016 Q1	$5.42M	Hold	38,300	–	–	0.3%	119
2015 Q4	$5.43M	Hold	38,300	–	–	0.3%	120
2015 Q3	$4.68M	Hold	38,300	–	–	0.27%	132
2015 Q2	$4.97M	Hold	38,300	–	–	0.26%	137
2015 Q1	$5.14M	Hold	38,300	–	–	0.27%	133
2014 Q4	$4.8M	Sell	38,300 -67,200	-64%	-$8.17M	0.26%	140
2014 Q3	$12.8M	Sell	105,500 -20,000	-16%	-$2.43M	0.7%	32
2014 Q2	$14.8M	Hold	125,500	–	–	0.79%	20
2014 Q1	$15.1M	Sell	125,500 -1,000	-0.8%	-$119K	0.82%	14
2013 Q4	$14.1M	Sell	126,500 -2,700	-2%	-$268K	0.77%	21
2013 Q3	$11.9M	Buy	129,200 +200	+0.2%	+$18.1K	0.69%	32
2013 Q2	$10.9M	Buy	+129,000	New	+$10.7M	0.66%	32

Other funds holding TMO

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

ECSS

Eurizon Capital SGR SpA Milan $37.3B AUM

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Lindsell Train London, United Kingdom $2.63B AUM 2.97% 1-Year Est. Return

EULAV Asset Management's TMO Position: Q2 2026 in Review

EULAV Asset Management sold out of Thermo Fisher Scientific (TMO) in Q2 2026, closing a stake of 2,400 shares — an estimated $1.18M sold.

EULAV Asset Management first reported a position in TMO in Q2 2013 and held it in 52 quarters. The position peaked at $88.1M in Q4 2021. 1,061 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

EULAV Asset Management reported no remaining Thermo Fisher Scientific position as of Q2 2026 after selling out during the quarter.
EULAV Asset Management sold 2,400 Thermo Fisher Scientific shares in Q2 2026, an estimated $1.18M.
EULAV Asset Management first reported a position in Thermo Fisher Scientific in Q2 2013 and held it in 52 quarters.
EULAV Asset Management's Thermo Fisher Scientific position peaked at $88.1M in Q4 2021.
1,061 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on EULAV Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.